Should I buy or sell Nkarta stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NKTX shares. View NKTX analyst ratings or view top-rated stocks .

What is Nkarta's stock price target for 2024?

5 analysts have issued twelve-month price objectives for Nkarta's stock. Their NKTX share price targets range from $9.00 to $26.00. On average, they expect the company's share price to reach $14.67 in the next year. This suggests a possible upside of 491.4% from the stock's current price. View analysts price targets for NKTX or view top-rated stocks among Wall Street analysts .

How have NKTX shares performed in 2023?

Nkarta's stock was trading at $5.99 at the beginning of 2023. Since then, NKTX stock has decreased by 58.6% and is now trading at $2.48. View the best growth stocks for 2023 here .

When is Nkarta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our NKTX earnings forecast .

How were Nkarta's earnings last quarter?

Nkarta, Inc. (NASDAQ:NKTX) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.06.

What other stocks do shareholders of Nkarta own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA) , Cronos Group (CRON) , Block (SQ) , Advanced Micro Devices (AMD) , ASML (ASML) , Beyond Meat (BYND) , Citigroup (C) , Salesforce (CRM) , CVS Health (CVS) and DraftKings (DKNG) .

(NKTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities acted as the underwriters for the IPO.

Who are Nkarta's major shareholders?

Nkarta's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (1.07%), Northern Trust Corp (0.66%), Monaco Asset Management SAM (0.48%), Innovis Asset Management LLC (0.28%), New York Life Investment Management LLC (0.20%) and Charles Schwab Investment Management Inc. (0.14%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam , Nadir Mahmood , Paul J Hastings, Paul J Hastings , Ra Capital Management, LP, Ralph Brandenberger and Simeon George. View institutional ownership trends .

How do I buy shares of Nkarta?

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Nkarta Stock Price, News & Analysis (NASDAQ:NKTX)

$2.48

+0.02 (+0.81%)

(As of 12:22 PM ET)

Compare

Today's Range: $2.47
▼
$2.61
50-Day Range: $1.31
▼
$3.14
52-Week Range: $1.28
▼
$9.20

Volume: 123,963 shs
Average Volume: 1.05 million shs
Market Capitalization: $121.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.67

Nkarta MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 491.4% Upside
$14.67 Price Target
Short Interest: Bearish
14.39% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.50) to ($2.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

423rd out of 949 stocks

Pharmaceutical Preparations Industry

191st out of 438 stocks

3.5

Analyst's Opinion

Consensus Rating
Nkarta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.67, Nkarta has a forecasted upside of 491.4% from its current price of $2.48.
Amount of Analyst Coverage
Nkarta has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
14.39% of the outstanding shares of Nkarta have been sold short.
Short Interest Ratio / Days to Cover
Nkarta has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Nkarta has recently increased by 1.73%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Nkarta does not currently pay a dividend.
Dividend Growth
Nkarta does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NKTX.

2.7

News and Social Media Coverage

News Sentiment
Nkarta has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Nkarta this week, compared to 1 article on an average week.
Search Interest
Only 8 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nkarta insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.60% of the stock of Nkarta is held by insiders.
Percentage Held by Institutions
80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Nkarta are expected to grow in the coming year, from ($2.50) to ($2.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nkarta is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nkarta is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nkarta has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nkarta Stock (NASDAQ:NKTX)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

NKTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NKTX Stock News Headlines

November 14, 2023 | finance.yahoo.com

T. Rowe Price Investment Management, Inc. Reduces Stake in Nkarta Inc

November 11, 2023 | benzinga.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Nkarta, Inc. (NASDAQ: NKTX) and Encourages Investors to Contact the Firm

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 10, 2023 | markets.businessinsider.com

Promising Developments and Financial Stability Propel Nkarta’s Buy Rating: An Insight into Expansion, Upcoming Trials, and Financial Position

November 10, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Adaptimmune Therapeutics (ADAP) and Corvus Pharmaceuticals (CRVS)

November 10, 2023 | finanznachrichten.de

Nkarta, Inc.: Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

November 9, 2023 | finance.yahoo.com

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

October 18, 2023 | msn.com

Raymond James Upgrades Nkarta (NKTX)

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

October 18, 2023 | finance.yahoo.com

Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug

October 17, 2023 | msn.com

Nkarta upgraded to strong buy by Raymond James

October 17, 2023 | msn.com

Nkarta stock jumps 20% on FDA, cash runway extension updates

October 17, 2023 | bizjournals.com

Peninsula biotech's stock soars as it cuts staff, focuses cell therapy on autoimmune diseases

October 17, 2023 | markets.businessinsider.com

Positive Outlook for Nkarta: FDA Approvals, Cost Reduction Initiatives, and Promising Expansion into Autoimmune Disease Treatment

October 17, 2023 | benzinga.com

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

October 17, 2023 | msn.com

What's Going With Cancer-Focused Nkarta Stock Today?

October 17, 2023 | markets.businessinsider.com

Nkarta’s Promising Pipeline Expansion and Cost-Saving Measures Drive Analyst’s Buy Rating

October 17, 2023 | finance.yahoo.com

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

October 17, 2023 | finanznachrichten.de

Nkarta, Inc.: Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

October 17, 2023 | markets.businessinsider.com

Nkarta Says FDA Clears IND Application For NKX019 To Treat Lupus Nephritis

October 16, 2023 | finance.yahoo.com

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

October 16, 2023 | finance.yahoo.com

Is Nkarta (NASDAQ:NKTX) In A Good Position To Deliver On Growth Plans?

October 9, 2023 | markets.businessinsider.com

Ventyx Biosciences Announces Positive Results From Trial Of VTX002 For Ulcerative Colitis

September 28, 2023 | markets.businessinsider.com

Promising Prospects for Ventyx Biosciences: A Comprehensive Analysis of VTX002’s Potential in Ulcerative Colitis Treatment

September 9, 2023 | benzinga.com

Nkarta Stock (NASDAQ:NKTX), Analyst Ratings, Price Targets, Predictions

August 14, 2023 | nasdaq.com

Mizuho Maintains Nkarta (NKTX) Buy Recommendation

August 14, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Ventyx Biosciences (VTYX)

See More Headlines

Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NKTX
CUSIP: N/A
CIK: 1787400
Web: www.nkartatx.com
Phone: 925-407-1049
Fax: N/A
Employees: 167
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.67
High Stock Price Target: $26.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +496.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,840,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -36.69%
Return on Assets: -27.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.97
Quick Ratio: 10.97

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.05 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 49,070,000
Free Float: 46,324,000
Market Cap: $120.71 million
Optionable: Not Optionable
Beta: -0.11

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Paul J. Hastings (Age 63)
CEO, President & Director
Comp: $938.41k
Dr. Alicia J. Hager (Age 53)
Chief Legal Officer & Corporate Secretary
Comp: $590.94k
Ms. Alyssa Levin C.A. (Age 38)
CPA, Chief Financial & Business Officer and Principal Accounting Officer
Dr. Ralph Brandenberger Ph.D. (Age 54)
Chief Technical Officer
Dr. James Trager Ph.D. (Age 60)
Chief Scientific Officer
Mr. Greg Mann
Vice President of Public Affairs and Investor Relations
Dr. David R. Shook M.D. (Age 45)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NKTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Nkarta stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NKTX shares.
View NKTX analyst ratings or view top-rated stocks.
What is Nkarta's stock price target for 2024?: 5 analysts have issued twelve-month price objectives for Nkarta's stock. Their NKTX share price targets range from $9.00 to $26.00. On average, they expect the company's share price to reach $14.67 in the next year. This suggests a possible upside of 491.4% from the stock's current price.
View analysts price targets for NKTX or view top-rated stocks among Wall Street analysts.
How have NKTX shares performed in 2023?: Nkarta's stock was trading at $5.99 at the beginning of 2023. Since then, NKTX stock has decreased by 58.6% and is now trading at $2.48.
View the best growth stocks for 2023 here.
When is Nkarta's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our NKTX earnings forecast.
How were Nkarta's earnings last quarter?: Nkarta, Inc. (NASDAQ:NKTX) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.06.

What other stocks do shareholders of Nkarta own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG).
When did Nkarta IPO?: (NKTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities acted as the underwriters for the IPO.
Who are Nkarta's major shareholders?: Nkarta's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (1.07%), Northern Trust Corp (0.66%), Monaco Asset Management SAM (0.48%), Innovis Asset Management LLC (0.28%), New York Life Investment Management LLC (0.20%) and Charles Schwab Investment Management Inc. (0.14%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George.
View institutional ownership trends.
How do I buy shares of Nkarta?: Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NKTX) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nkarta Stock Price, News & Analysis (NASDAQ:NKTX)

Nkarta MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Nkarta Stock (NASDAQ:NKTX)

NKTX Stock Price History

NKTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NKTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™